LivaNova PLC (NASDAQ:LIVN) Shares Bought by Fox Run Management L.L.C.

Fox Run Management L.L.C. boosted its position in shares of LivaNova PLC (NASDAQ:LIVN) by 183.7% in the fourth quarter, HoldingsChannel.com reports. The fund owned 19,843 shares of the company’s stock after acquiring an additional 12,848 shares during the quarter. Fox Run Management L.L.C.’s holdings in LivaNova were worth $919,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of LIVN. Atria Investments Inc lifted its holdings in shares of LivaNova by 6.2% in the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock valued at $297,000 after buying an additional 331 shares during the period. GSA Capital Partners LLP acquired a new position in shares of LivaNova in the 3rd quarter valued at about $292,000. Segall Bryant & Hamill LLC acquired a new position in shares of LivaNova in the 3rd quarter valued at about $2,127,000. Intech Investment Management LLC lifted its holdings in shares of LivaNova by 80.4% in the 3rd quarter. Intech Investment Management LLC now owns 15,815 shares of the company’s stock valued at $831,000 after buying an additional 7,049 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in LivaNova by 17.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company’s stock worth $32,678,000 after purchasing an additional 93,311 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Price Performance

LIVN stock opened at $39.48 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The business has a 50 day simple moving average of $45.31 and a 200-day simple moving average of $48.74. The firm has a market capitalization of $2.15 billion, a PE ratio of 94.00 and a beta of 1.10. LivaNova PLC has a 1 year low of $36.85 and a 1 year high of $64.48.

Analysts Set New Price Targets

A number of research firms recently weighed in on LIVN. The Goldman Sachs Group reduced their price target on LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a report on Monday, March 3rd. Wolfe Research lowered LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. Mizuho cut their price objective on LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and set a $64.00 price objective on shares of LivaNova in a research note on Monday, March 17th. Finally, StockNews.com lowered LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $61.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.